Pharmaceutical company Dr Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE: RDY) on Thursday announced the availability of its antipsychotic medication Fluphenazine Hydrochloride Tablets, USP in the US market.
Fluphenazine Hydrochloride Tablets, USP are a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg and 10 mg, and are approved by the US Food and Drug Administration (FDA).
The Prolixin brand and generic had US sales of approximately USD134m MAT for the 12 months ending in December 2020, according to IQVIA Health.
Fluphenazine is used in the treatment of chronic psychoses such as schizophrenia and psychotic symptoms such as hallucinations, delusions and hostility.
Privo Technologies reports progress in oral cancer trial
BeOne Medicines' sonrotoclax receives FDA Breakthrough Therapy Designation for MCL
Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development
Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA
Rigel Pharmaceuticals begins dose expansion phase of R289 study in lower-risk MDS
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Oxford Biomedica expands US operations with acquisition of viral vector facility in North Carolina
DarioHealth and OneStep partner to integrate fall risk technology into digital health platform
Ananda Pharma achieves key Phase 1 milestone for MRX1 CBD program
Alvotech and Advanz Pharma announce EMA acceptance of AVT23 marketing application